Seborrheic Dermatitis Treatment Market Research Report - Global Forecast till 2027

Global Seborrheic Dermatitis Treatment Market Research Report: By Treatment Type (Antifungal Products, Corticosteroid Lotions, Sulfur Products), By Route of Administration (Oral, Topical) and By End-User (Hospital Pharmacies, Retail Pharmacies, Others) – Forecast to 2027

ID: MRFR/HC/7027-HCR | February 2021 | Region: Global | 90 pages

Please note that the assessment period of report has been updated from 2019-2025 to 2020-2027. Cordially fill the sample form for updated data.

Market Forecast

Seborrheic Dermatitis Treatment Market is expected to cross USD 3.28 Billion by 2025 at a CAGR of 10.5 %.

Market Synopsis

Seborrheic dermatitis is a chronic inflammatory disorder that mostly affects the head and face. Primarily environmental, genetic, and general health problems are the cause of this disorder. The exact cause of seborrheic dermatitis remains unknown, but factors such as a change in hormone is the primary cause of this disease. It frequently affects people post-puberty. The prevalence of seborrheic dermatitis has been rising significantly in recent years. In the US alone, approximately 300 people are diagnosed with seborrheic dermatitis annually making it a reasonably common dermatological disorder worldwide. Some factors influencing the market growth are the rising awareness of personal hygiene, advancement in treatment options for seborrheic dermatitis, and growing awareness regarding seborrheic dermatitis.

Market Influencer

Development in the seborrheic dermatitis treatment is expected to influence the market growth during the forecast period.

Market Drivers

  • Rising prevalence of dandruff: Seborrheic dermatitis affected around 2.35% to 11.3% of the entire population in the US in 2018.

  • The growing global geriatric population that are most commonly affected by seborrheic dermatitis

  • Clinical advancements in seborrheic dermatitis therapy

  • Increasing research & development for the development of new drugs for the treatment of seborrheic dermatitis

  • Rising awareness of seborrheic dermatitis

Market Restraints

  • Stringent regulatory policies

  • Limited primary care services


By Treatment Type

  • Antifungal Products: The largest segment of the market. Pharmacological treatment options such as antifungal preparations are the most widely available and accepted treatment options for seborrheic dermatitis. Antifungal products constitute a combination of various ingredients including selenium sulfide, pyrithione zinc, azole agents, sodium sulfacetamide, and topical terbinafine.

  • Corticosteroid Lotions: Seborrheic dermatitis generally afflicts elderly people. Topical corticosteroid solutions, lotions, and ointments are also used in the treatment of seborrheic dermatitis.

  • Sulfur Products: Sulfur has antifungal, antibacterial, and keratolytic properties. Sulfur on its own or combined with agents such as sodium sulfacetamide or salicylic acid has demonstrated efficacy in the treatment of many dermatological conditions, including seborrheic dermatitis.  

By Route of Administration

  • Oral: The largest segment in the market. Various oral antifungal medicines are used for the treatment of seborrheic dermatitis. The oral route of administration is preferred in cases of chronic seborrheic dermatitis.

  • Topical: Topical agents such as creams, lotions, ointments, and shampoos are also used in treating seborrheic dermatitis.

By End-User

  • Hospital Pharmacies: The largest segment, hospital pharmacies, are the usual primary points for diagnosis, treatment, and rehabilitation of individuals afflicted with most diseases and disorders including seborrheic dermatitis. Growing awareness and increasing efficiency of seborrheic dermatitis treatment are projected to drive the growth of this segment during the forecast period.

  • Retail Pharmacies: A small segment. Retail pharmacies provide immediate pain relief drugs and rudimentary drugs for seborrheic dermatitis.

  • Others: This segment includes home care and senior citizen centers.

By Region

  • Americas: The largest regional market. The prevalence of seborrheic dermatitis treatment is high in the Americas. The region also has a well-established healthcare industry. Of the entire population, around 80.2% of people in the US were suffering from seborrheic dermatitis in 2017.

  • Europe: An increasing geriatric population is leading to a rise in the number of seborrheic dermatitis.

  • Asia-Pacific: The fastest-growing regional market. Asia-Pacific has been witnessing a surge in the number of people afflicted with seborrheic dermatitis due to the clinical advancement for its therapy. Seborrheic dermatitis is an increasing problem in Asia. Approximately 3,000 patients were diagnosed with seborrheic dermatitis disorder in Korea in 2018, whereas in Japan, around 298 people were diagnosed with seborrheic dermatitis in 2017.

  • Middle East & Africa: The smallest market due to limited healthcare infrastructure.

Key Players

  • Sonoma Pharmaceuticals (US)

  • Merck (US)

  • Hikma Pharmaceuticals (UK)

  • Allen and Hanburys (UK)

  • GlaxoSmithKline (UK)

  • Bausch Health (Canada)

  • Valent Pharmaceutical (UK)

  • West-Ward Pharmaceutical Corp. (US)

Frequently Asked Questions (FAQ) :

seborrheic dermatitis market is projected grow at approximately 10.5% CAGR during the assessment period (2019-2025).

The valuation of the global seborrheic dermatitis market is estimated to increase to USD 3.28 BN by the end of 2025.

The corticosteroid lotions segment by treatment type holds the majority shares in the global seborrheic dermatitis market.

North America holds the largest share in the global seborrheic dermatitis market, followed by Europe and the Asia Pacific, respectively.

Merck (US), Sonoma Pharmaceuticals (US), Hikma Pharmaceuticals (UK), GlaxoSmithKline (UK), Allen and Hanburys (UK), Bausch Health (Canada), West-Ward Pharmaceutical Corp. (US), and Valent Pharmaceutical (UK), are some of the major players operating in the global seborrheic dermatitis market.

This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.